Phaseline

Companies › GC Cell

GC Cell: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Immuncell-LC
Autologous activated T lymphocyte
–Phase 3Pancreatic Ductal AdenocarcinomaDec 2026
GCC2005
CAR-NK cell therapy
–Phase 1Lymphoma, T-CellAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04969731Immuncell-LCPhase 3Pancreatic Ductal AdenocarcinomaOncologyDec 2026
NCT06699771GCC2005Phase 1Lymphoma, T-CellOncologyAug 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

GeneQuantum Healthcare (Suzhou) Sellas Life Sciences Group Kura Oncology Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) RayzeBio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.